IMPORTANT: UPDATED Guidance for Patients on COVID-19 including Vaccine Information»
According to the results of a study presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO), graft vs host disease (GVHD) prophylaxis with posttransplant
Patients, family members, friends and advocates, sign up, tell your story, create a team, and set a goal to support AAMDSIF!
Anywhere you and your friends choose to, walk, run, cycle – in a park, through your neighborhood, or on a treadmill – anytime leading up to or during the day of the 24th.
Getting the right diagnosis can be difficult and many patients with
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Efficacy was evaluated in KD025-213 (NCT03640481), a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.
AAMDSIF is pleased to announce that we will host a support group for patients and siblings ages 13-17. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants. Parent/Guardian permission is required to participate in the group.
Dr. Catherine Lee will provide a comprehensive overview of chronic and acute graft vs host disease ("GvHD") which is a complication of bone marrow transplant. While some patients have very mild GvHD, many patients have more severe and long term disease. Dr.
Constandina Herbert, MN, RN, BMTCN is the Nursing Supervisor, Blood and Marrow Transplant Clinic at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Ms. Herbert works with patients, families, and caregivers as they navigate the transplant process.
Dr. Eric Yang is currently an Associate Clinical Professor of Medicine at the Ronald Reagan University of California, Los Angeles Medical Center. He obtained his undergraduate and medical degrees at the University of Illinois at Chicago College of Medicine, and completed his internal medicine residency and cardiology fellowship at Harbor-UCLA Medical Center, where he served as chief fellow.